These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 28714406)

  • 1. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
    Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
    Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
    Ngambenjawong C; Gustafson HH; Pun SH
    Adv Drug Deliv Rev; 2017 May; 114():206-221. PubMed ID: 28449873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated macrophages: implications in cancer immunotherapy.
    Petty AJ; Yang Y
    Immunotherapy; 2017 Mar; 9(3):289-302. PubMed ID: 28231720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers.
    Kielbassa K; Vegna S; Ramirez C; Akkari L
    Front Immunol; 2019; 10():2215. PubMed ID: 31611871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage-based cancer immunotherapy: Challenges and opportunities.
    Bai H; Feng L; Schmid F
    Exp Cell Res; 2024 Sep; 442(1):114198. PubMed ID: 39103071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor-associated macrophages for cancer immunotherapy.
    Shu Y; Cheng P
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188434. PubMed ID: 32956767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance.
    Jiang T; Chen X; Ren X; Yang JM; Cheng Y
    Drug Resist Updat; 2021 May; 56():100752. PubMed ID: 33765484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of anticancer therapies with tumor-associated macrophages.
    Mantovani A; Allavena P
    J Exp Med; 2015 Apr; 212(4):435-45. PubMed ID: 25753580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery.
    Clancy T; Dannenfelser R; Troyanskaya O; Malmberg KJ; Hovig E; Kristensen V
    Curr Pharm Des; 2017; 23(32):4716-4725. PubMed ID: 28699527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-education of macrophages as a therapeutic strategy in cancer.
    Kowal J; Kornete M; Joyce JA
    Immunotherapy; 2019 Jun; 11(8):677-689. PubMed ID: 31088236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
    Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
    Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumor-associated macrophages as an antitumor strategy.
    Cheng N; Bai X; Shu Y; Ahmad O; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.